Potentiation of apomorphine-induced climbing behaviour in mice by d-LSD

Sovilla, Jean Yves; Magistretti, Pierre J.; Schorderet, Michel

doi:10.1016/0364-7722(79)90004-3

Cited by 1 publication

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Possibly, MAM exerts partial intrinsic activity at dopamine receptors (likely the D2 receptor), but this is speculative and needs to be addressed in future research. Potentiation of climbing at 10 mg/kg MAM was also observed, comparable to the potentiation of climbing seen with different classes of compounds acting on dopamine D1 receptors [54], α-adrenergic receptors [55], µ-opioids [56,57] and serotonergic receptors [58,59]. This may explain the complexity of AAPs by acting on, besides the D2 receptor, multiple additional target receptors and suggests the possibility that MAM could have one (or more) of these targets.…”

Section: Discussionsupporting

confidence: 60%

The Natural Protoalkaloid Methyl-2-Amino-3-Methoxybenzoate (MAM) Alleviates Positive as well as Cognitive Symptoms in Rat and Mouse Schizophrenia Models

Bright,

Maas,

Verheij

et al. 2024

View full text Add to dashboard Cite

The development of new antipsychotics with pro-cognitive properties and less side effects represents a priority in schizophrenia drug research. In this study, we present for the first time a pre-clinical exploration of the effects of the promising natural atypical antipsychotic Methyl-2-Amino-3- Methoxybenzoate (MAM), a brain-penetrable protoalkaloid from the seed of the plant Nigella dama- scena. Using animal models related to hyperdopaminergic activity, namely the pharmacogenetic apo- morphine (D2/D1 receptor agonist)-susceptible (APO-SUS) rat model and pharmacologically induced mouse and rat models of schizophrenia, we found that MAM reduced gnawing stereotypy and climb- ing behaviours induced by dopaminergic agents. This predicts antipsychotic activity. In line, MAM antagonized apomorphine-induced c-Fos and NPAS4 mRNA levels in post-mortem brain nucleus ac- cumbens and dorsolateral striatum of APO-SUS rats. Furthermore, phencyclidine (PCP, an NMDA re- ceptor antagonist) and 2,5-Dimethoxy-4-iodoamphetamine (DOI, a 5HT2A/2C receptor agonist) in- duced prepulse inhibition deficits, reflecting the positive symptoms of schizophrenia, which were res- cued by treatment with MAM and atypical antipsychotics alike. Post-mortem brain immunostaining revealed that MAM blocked the strong activation of both PCP- and DOI-induced c-Fos immunoreac- tivity in a number of cortical areas. Finally, during a 28-day subchronic treatment regime, MAM did not induce weight gain, hyperglycemia, hyperlipidemia or hepato- and nephrotoxic effects, side effects known to be induced by atypical antipsychotics. MAM also did not show any cataleptic effects. In conclusion, its brain penetrability, the apparent absence of preclinical side effects, and its ability to an- tagonize positive and cognitive symptoms associated with schizophrenia make MAM an exciting new antipsychotic drug that deserves clinical testing.

show abstract